Ludwig San Diego
AT EVERY STEP OF THE RESEARCH PROCESS FROM THE LAB TO THE CLINIC, WE ARE PURSUING INNOVATIVE WAYS TO PREVENT AND CONTROL CANCER.
Stephen Hodi, an investigator at Ludwig Harvard, reports that 34 percent of patients with advanced melanoma who were treated the immunotherapy nivolumab alone were still alive five years later.
Research conducted by more than 70 Ludwig scientists will be presented in symposiums, plenaries and poster sessions, and Ludwig researchers will participate in workshops and meet-the-expert sessions.
Ludwig and CRI are partnering with MedImmune and VentiRx to test a combination immunotherapy for metastatic ovarian cancer, a disease for which patients today have few treatment options.